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Abstract: The use of kinase-directed precision medicine has been heavily pursued since the discovery and development 
of imatinib. Annually, it is estimated that around ~20,000 new cases of TRK-driven cancers are diagnosed, with the 
majority of cases exhibiting a TRK genomic rearrangement. In this perspective article, we discuss current development 
and clinical applications for TRK precision medicine by providing the following: (1) The biological background and 
significance of the TRK kinase family, (2) A compilation of known TRK inhibitors and analysis of their co-crystal 
structures, (3) An overview of TRK clinical trials, and (4) Future perspectives for drug discovery and development of 
TRK inhibitors. 
 
 
 
 
 
 
 
 
 
Introduction 
The tropomyosin receptor kinase (TRK) family of enzymes are transmembrane, receptor tyrosine kinases (RTK) 
that regulate synaptic strength and plasticity in the mammalian nervous system.
1-8
 In this role, the TRK family regulates 
cell differentiation, proliferation, survival, and pain.
9-23
 There are three members of the TRK family: TRKA (encoded by 
NTRK1 gene), TRKB (NTRK2), and TRKC (NTRK3), which have all been implicated to drive initiation and progression 
of malignancies.
24-41
 Similar to the BCR-ABL gene fusion product that drives chronic myelogenous leukemia (CML),
42
 
NTRK rearrangements and fusion gene products have been observed in numerous tumor types, which has been 
comprehensively reviewed by Vaishnavi, et al and Amatu, et al.
43-44
 Unlike CML, however, the incidence of NTRK fusion 
genes in each specific tumor type overall is rare. This generates profound difficulties for patient identification and 
adequate recruitment for clinical trials. For instance, NTRK2 gene fusions have been identified in 0.2% of lung 
adenocarcinoma,
45
 which represents approximately 184 patients of 92,138 diagnosed in 2010 in the USA.
46
 On the other 
end of the spectrum, NTRK3 fusion genes have been identified in virtually all secretory breast carcinomas and of 
mammary analogue secretory carcinomas (MASC), an extremely rare tumor of the salivary (in general, of the parotid) 
gland.
47
 In fact, the defining characteristic of MASC, when compared to other salivary carcinomas, is an NTRK gene 
fusion.
47
 In addition, NTRK fusions are found in about 50% of pediatric diffuse intrinsic pontine glioma and non-
brainstem glioblastoma.
48
 In major cancer subgroups, NTRK fusions occur in 3.3% of lung cancers,
45, 49
 2.2% of colorectal 
cancers,
45, 49-52
 16.7% of thyroid cancers,
45, 53-54
 2.5% of glioblastomas, and 7.1% of pediatric gliomas.
43, 55
 Finally, similar 
to the receptor tyrosine kinase RET (rearranged during transfection), NTRK fusions (particularly ETV6-NTRK3) are 
common in post-Chernobyl radiation-induced papillary thyroid carcinomas.
56-57
 Thus, targeting TRK oncogenes is an 
attractive therapeutic approach for a diverse, frequently rare set of cancers. 
 The primary method to target TRK oncogenes is the use of small molecule kinase inhibitors. Because gene fusion 
products are the major oncogenes observed, other targeting strategies, such as antibody therapy, will not be effective since 
transmembrane tyrosine kinase fusions frequently lack an extracellular domain.
58
 In this case, the fusion proteins are only 
susceptible to small molecule inhibition.
59-61
 In general, small molecules are designed to target the adenosine triphosphate 
(ATP) binding site of TRK to block catalytic activity. This is based on the principle that protein kinases catalyze a 
phosphoryl transfer to a downstream substrate and only have micromolar affinity for ATP.
62
 Since turnover is rapid and 
 
 
 
 
kinase affinity for ATP is weak, small molecules can effectively bind and inhibit TRK despite a high cellular 
concentration of ATP. Because of the druggability of the TRK enzyme class, a number of attempts to target TRKs have 
been completed. In this perspective article, we discuss current development and clinical application of TRK-targeted 
cancer therapy including (1) The biological background and significance of the TRK family, (2) A compilation of known 
TRK inhibitors and analysis of TRK/inhibitor co-crystal structures, (3) An overview of TRK clinical trials, and (4) Future 
perspectives for drug discovery and development of TRK inhibitors. 
TRK Biology and Signaling 
The TRK oncogene was initially discovered in colon cancer in which the cytoskeletal protein tropomyosin was 
fused to an unknown, catalytically active kinase domain.
50, 63
 Further studies identified the kinase as a single-pass receptor 
tyrosine kinase expressed in the developing central nervous system and was given the name tropomyosin receptor kinase. 
In the extracellular region of TRK, there is a leuc ine rich motif, two cysteine-rich domains, and two immunoglobulin-like 
domains and all are essential for ligand recognition and binding.
64-66
 Unlike typical RTKs, the TRK intracellular region is 
small and comprised of roughly 70 amino acids before and 15 amino acids after the kinase domain.
64-65
 In comparison to 
other RTKs, TRK is most similar to the insulin receptor and has been implicated in insulin signaling.
67
 
 
 
 
 
 
Figure 1. Schematic view of TRK receptor tyrosine kinases and major signal transduction pathways involved in cell 
differentiation, proliferation, and survival. TRKA is activated by nerve growth factor (NGF), TRKB is activated by brain-
derived neurotrophic factor (BDNF), and TRKC is activated by neurotrophin-3 (NT3). RAS, rat sarcoma oncogene; RAF, 
rapidly accelerated fibrosarcoma oncogene; MEK, mitogen-activated protein kinase; ERK, extracellular signal-regulated 
kinase; GRB2, growth factor receptor-bound protein 2; SHC, SRC homology 2 domain containing; PI3K, 
phosphatidylinositol-4,5-bisphosphate 3-kinase; AKT, v-AKT murine thymoma viral oncogene homologue; PLCγ, 
phospholipase C-γ; DAG, diacyl-glycerol; PKC, protein kinase C; IP3, inositol trisphosphate.  
The TRK family is comprised of three distinct isoforms: TRKA, TRKB, and TRKC. A major difference between 
all three isoforms is the ligand that activates the receptor. TRKA is activated by nerve growth factor (NGF),
68-70
 TRKB is 
activated by brain-derived neurotrophic factor (BDNF),
69-70
 while TRKC is primary activated by neurotrophin 3 (NT3) 
(Figure 1).
71-72
 The kinase domains of TRKA, TRKB, and TRKC share between 72% and 78% sequence identity.
73
 When 
looking at the residues that interact directly with ATP in the active site,
74
 TRKA and TRKB share 95% sequence identity 
 
 
 
 
while TRKB and TRKC are completely identical.
73
 In the TRK domain, the TRKA hinge is more structurally constrained 
compared to TRKB and TRKC, suggesting the hinge environment differs between TRK isoforms.
74
 Further, the kinase 
insert domain of the TRK family is not structurally conserved, which is another key difference within the family.
74
 
Similar to the RTK superfamily, TRKs dimerize in response to ligand binding (Figure 1 and 2).
75
 After ligand 
binding, TRKs autophosphorylate each monomer followed by rapid phosphorylation of the kinase activation loop.
76-78
 
These phosphorylation events enhance catalytic activity of the kinase. To generate attachment sites for adapter proteins, 
the NPXY motif (Y490 in TRKA) in the juxtamembrane domain and the YLDIG motif (Y785 in TRKA) in the carboxy 
terminus are phosphorylated.
79-82
 These phosphorylation events create docking sites for SRC Homology Domain 2 (SH2) 
and Phosphotyrosine binding domain (PTB) containing proteins, such as SHC and phospholipase C-gamma (PLC-
gamma). After binding, SHC and PLC are activated through TRK-catalyzed phosphorylation.
44, 83
 
SHC was the first adaptor protein identified to bind to the phosphorylated NPXY motif of TRK, which results in 
the activation of the AKT and RAS canonical pathways.
80-82, 84
 After SHC is activated, a secondary adaptor protein, 
growth factor receptor-bound protein 2 (GRB2),
85
 is recruited and facilitates GTP-loading of RAS via the guanine 
nucleotide exchange factor, SOS.
86
 The activated, GTP-bound form of RAS activates the MAP kinase cascade, which 
includes activation of RAF, MEK, and ERK.
87
 The ERK kinase translocates into the nuclear membrane activating 
transcription of target genes involved in cell growth, survival, and proliferation.
88
 
Activation of the AKT pathway occurs via recruitment of SHC and GRB2 to the NPXY motif of TRK, which 
signals through the intermediary molecule, GRB2-associated-binding protein 1 (GAB1). This simulates activity of 
phosphoinositide 3-kinase (PI3K) leading to phosphorylation of PI4,5 lipids at the 3’-position.89 On AKT, there is a 
conserved pleckstrin homology (PH) domain, which interacts with the 3’-phosphorylated lipids leading to AKT 
activation.
90-93
 AKT activation leads to increased expression of cell survival and proliferation genes that enhance pro-
survival phenotypes mediated through TRK receptors.
94-98
 
 
TRK Implication in Cancer 
Genetic mutations in the TRK family have been reported in many cancers, namely carcinomas of the colon, 
thyroid, lung, ovary, breast (secretory breast carcinoma), salivary gland (mammary analogue secretory carcinoma), 
 
 
 
 
pancreas, melanoma, spitzoid neoplasms, cholangiocarcinoma, stromal tumors (congenital fibrosarcoma, congenital 
mesoblastic nephroma, soft tissue sarcoma, gastrointestinal stromal tumor, inflammatory myofibroblastic tumor), brain 
tumors (pediatric glioma, astrocytoma and glioblastoma) and leukemia (Table 1 and Figure 3).
43, 99-100
 
49, 51, 53, 57, 101
 Within 
the TRK family, TRKA is the most commonly identified oncoprotein, which is found at a rate of approximately 7.4% 
across multiple tumor types.
43
 Following is TRKC and then TRKB, which are found at rates of 3.4% and 0.4%, 
respectively. The majority of TRKB mutations have a frequency of less than 0.5% and many TRKC mutations have a 
frequency of less than 1.0%.
49
 
 
Figure 2. Ligand-independent signaling leading to constitutive TRK activation can occur through three, distinct 
mechanisms: A genomic rearrangement event; Extracellular point mutations; or Truncations of the extracellular domain.  
(1) In a genomic rearrangement event the kinase domain of TRK is fused to an unrelated protein, typically called the 
fusion partner. In this example, a cytoplasmic chimeric TRK fusion is shown without the transmembrane (TM) domain. 
Of note, TRK fusions can occur with or without the TM domain.
102
 (2) Point mutations can occur in the extracellular 
domain of TRK, generating a TRK oncogene with transforming abilities.  Point mutations that are transformative under 
laboratory conditions have been identified at P203A and C345S.
103-104
 (3) Through in-frame deletions and alternative 
 
 
 
 
splicing events, the TRK kinase can present with a truncated extracellular domain. These aberrant gene products have 
been identified in AML and neuroblastoma.
105-107
 FP: fusion partner. KD: kinase domain. 
 
When an NTRK gene fusion occurs, the translocation event generates a hybrid oncogene composed of the active 
TRK kinase domain linked to an unrelated gene or fusion partner, triggering constitutive activation or overexpression of 
the TRK protein (Figure 2).
44, 53
 The resulting aberrantly expressed, novel oncogene can occur with or without the 
transmembrane domain.
43, 102
 Certain mutations in the extracellular domain of TRKA, namely P203A and C345S, have 
been identified as transforming under laboratory conditions but have yet to be identified in human tumor samples.
103-104
 
On the other hand, in-frame deletions (TRKA) and splice variants (TRKAIII) of NTRK1 have been functionally 
identified and characterized in human tumor samples.
52, 105-107
 The TRKA in-frame deletion, identified in acute myeloid 
leukemia (AML), contains a truncated extracellular domain that can transform both epithelial and fibroblast cells.
107
 The 
TRKAIII splice variant, identified in neuroblastoma, has deletions in exons 6, 7, and 9, which results in the loss of Ig-like 
C2-type I (IG-C2) and glycosylation sites in the extracellular domain (Figure 2).
52, 106
 TRKA activating mutations from 
either genomic rearrangements, point mutations, deletions, or splice variants compromise the ability to regulate the kinase 
domain. This suggests that a key attribute to the oncogenic potential of TRK is the loss of the extracellular domain and/or 
its function. 
 
Table 1. Oncogenic TRK fusions are found across multiple tumor types
a 
 
Cancer Site Estimated US Cases / yr TRKA% TRKB% TRKC% 
Lung Adenocarcinoma (NSCLC) 92,138
46
 3.3
49
 0.2
45
 / 
Colorectal 135,430
108
 1.5
49-50, 52
 
51
 / 0.7
45
 
Intrahepatic cholangiocarcinoma 2,970
109-110
 3.6
111
 / / 
Papillary thyroid cancer 45,496
108, 112
 12.3
53
 / 14.5
54, 113
 
Glioblastoma 11,376
108, 114
 1.25
55
, 
115
 / / 
Head and neck squamous cell carcinoma 63,030
116
 / 0.2
45
 0.2
117
 
Mammary analogue secretory carcinoma 151
108, 118
 / / 100
119
 
Ph-like acute lymphoblastic leukemia 1,192
120-121
 / / 0.7
122
 
Acute myeloid leukemia 15,976
121, 123
 / / 0.0125
57, 124
 
 
 
 
 
Skin cutaneous melanoma 87,110
121
 / / 0.3
45
 
Secretory breast carcinoma 252
121, 125
 / / 92
126
 
 Estimated Total Cases / yr 10,917 310 8,325 
 Estimated Percent of Cases / yr 55.8% 1.6% 42.6% 
a
 Only positive studies are listed, and thus the actual prevalence may be lower than reported. 
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Figure 3: (A) Estimated contribution of TRKA/B/C mutations to all TRK-driven malignancies. Data is based on estimated 
incidence of cancers at major sites and contribution of TRK mutations at each site. It is estimated that a total of 19,552 
cancers are diagnosed each year that have a TRK oncogene. Of the new cases, 55.8% (10,917) are TRKA, 42.6% are 
TRKC (8,325) and 1.6% (310) are TRKB. Because of the limited sequencing data, the actual amount of TRK-driven 
tumors could be significantly greater or lower depending on robustness of sample size, sample selection, and data 
analysis. Also, tumors with a TRK mutation could be dependent on a separate pathway. (B) Estimated number of cancers 
positive for TRKA. Lung (lung adenocarcinoma), IC (intrahepatic cholangiocarcinoma), PTC (papillary thyroid cancer), 
and Glio (glioblastoma). 
In the tumor environment, TRK oncogenes stimulate uninhibited signaling through the RAS/RAF and PI3K/AKT 
pathways
49, 127-129
 The preferred signaling cascade is cell-specific, with dominance from the RAS/RAF pathway observed 
in both colorectal (KM-12) and lung (CUTO-3) cancers. In certain cell types, TRK oncogenic signaling also occurs 
through the PI3K/AKT and STAT3 signal transduction pathways
49
, and in other cases the RAS/RAF and PI3K/AKT 
 
 
 
 
cascades are activated in concert.
130
 Because of multifaceted pathway activation, TRK oncogenes are potent and highly 
oncogenic by stimulating both antiapoptotic and proproliferative pathways.
131
 Further, TRK fusion oncogenes have been 
identified as important mediators to stimulate early tumor progression.
132
 Taken together, inhibition of TRK oncogenes 
can have chemotherapeutic and chemopreventive effects and, subsequently, has become a hotbed for therapeutic 
discovery efforts. In this perspective, we summarize TRK inhibitors from peer-reviewed literature; compounds from 
patents have been previously reviewed by McCarthy and Bailey et al.
133-135
 
 
TRK Inhibitors 
The following section represents a comprehensive overview of known TRK inhibitors and their corresponding 
discovery and development efforts. Because most TRK-activating mutations alter or eliminate the extracellular domain,
59-
61
 antibodies directed at TRK or TRK growth factors will not be effective as anticancer agents. Thus, all inhibitors 
reviewed are small-molecule kinase inhibitors that primarily target the TRK kinase domain. The inhibitors are at various 
stages of development from exploratory research, pre-clinical research, to clinical trials. Inhibitors have been classified 
based on their interactions with TRK
136
 and are presented according to their binding modes. TRK inhibitors can be broken 
down into four, distinct subtypes based on ligand/binding interactions. The classifications are (A) Type I, (B) Type II, (C) 
Type III, and (D) Type IV.
137
 (A) Type I TRK inhibitors are ATP competitive and bind to the ATP-binding site. The 
majority of TRK inhibitors under clinical investigation are Type I. (B) Type II TRK inhibitors are ATP non-competitive 
and exhibit non-competitive or pseudo-competitive binding kinetics. Type-II inhibitors bind at the ATP-binding site and 
also to an adjacent allosteric pocket. Only a subset of kinases permit such binding, including TRK, a binding mode which 
can be incorporated into compound design to increase selectivity. (C) Type III TRK inhibitors bind to the kinase domain 
outside of the ATP-binding site. Unlike Type II inhibitors, Type III inhibitors are true allosteric inhibitors and can exploit 
unique, kinase-specific functionality to help achieve selectivity among TRK isoforms. (D) Type IV TRK inhibitors bind 
to a region other than the kinase domain. The majority of kinases are expressed as multi-domain proteins with a catalytic 
domain and a regulatory domain. Type IV inhibitors can interrupt key protein-protein interactions or ligand interactions 
that limit activity of the kinase domain.
138
 Because TRK genomic rearrangements often pair the TRK kinase domain to an 
 
 
 
 
unrelated gene, it is unclear how effective the anticancer properties will be for Type IV TRK inhibitors. Type IV TRK 
inhibitors are not reviewed in this perspective. 
Type I TRK Inhibitors 
 
Figure 4. (A) Identification of compounds 1-3, 1-4, and 1-5; (B) Co-crystal structure of compound 1-3 in TRKA (PDB ID: 
4AOJ, 2.75 Å). The kinase is depicted in yellow ribbons and the hydrogen bonds are illustrated in blue dashed lines.  
Type-I TRK inhibitors exhibit vast diversity in compound architecture, which will alter activity and selectivity 
profiles of the compounds. This helps to better define chemical space that is relevant to TRK inhibit ion and suggests 
points of refinement for future drug discovery efforts. Wang et al reported 4-aminopyrimidines with TRK inhibitory 
activity from a high throughput screening effort against TRKB (Figure 4A).
139
 The group discovered compound 1 with 
activity on TRKA and B (IC50 = 0.27 M and 1.1 M, respectively). To complete SAR studies on 1, the isoxazole was 
replaced with a phenyl group, and halogen substitution at the 4-position of phenyl was found to improved potency (1-1a 
and 1-1b, TRKA IC50s were 0.10 M and 0.36 M, respectively).
139
 SAR studies at R
2
 indicated that the (S)-enantiomer is 
preferred over the (R)-enantiomer (1-1c vs 1-1d and 1-1e, TRKA IC50s were 0.65 M vs 0.10 M and 0.006 M, 
respectively). On the pyrimidine ring system, substituting bromine to fluorine or chlorine had little effect on TRKA 
activity (1-2a and 1-2b, TRKA IC50s were 0.017 M vs 0.004 M, respectively).
139
 Replacement of cyclopropyl at R
4
 
 
 
 
 
with isopropoxy is tolerated (1-2c, TRKA IC50 = 0.006 M), but altering aliphatic length or bulk decreases potency likely 
from geometric constraints at the TRKA hinge region (1-2d and 1-2e, TRKA IC50s were 0.081 M and 3 M, 
respectively). Further optimization and refinement strategies furnished orally bioavailable compound 1-3 (AZ23).
139
 
Compound 1-3 was active against TRKA and B (IC50 = 0.002 M and 0.008 M, respectively) and exhibited anticancer 
activity by oral dosing in a TRKA-driven allograft model and TRK-expressing xenograft model of neuroblastoma.
140
 In 
2012, a ring fusion study of this scaffold was reported by the same research group.
141
 Two different ring fusion strategies 
were employed to generate imidazo[4,5-b]pyridine and purine derivatives. Representative compounds of the two 
scaffolds, 1-4 and 1-5, exhibited potent TRK inhibition. Both compounds displayed IC50 values of 0.0005 M against 
TRKA-dependent MCF10A cells (MCF10A-TRKA-Δ), and were also active in mice bearing 3T3-TRKA-Δ tumors.141 
In the co-crystal structure of compound 1-3 with TRKA (Figure 4B), TRKA is found in an inactive conformation 
with the C-helix pushed into a non-catalytically active orientation.
141
 Compound 1-3 forms two hydrogen bonds at the 
hinge region with the pyrazole-moiety, and interacts with the amide backbone of Glu590 and Met592. The isopropoxy 
group is oriented toward Phe589, which is the gatekeeper amino acid. The fluoropyridine ring engages in an interaction 
with Leu657, and the fluorine atom is in close proximity to Gly667.
142
 Numerous TRK kinase inhibitors exploit this 
region to increase selectivity and potency.
141
 Based on the crystal structure, compound 1-3 is a Type-I kinase inhibitor. 
 
 
 
 
 
 
Figure 5. (A) Identification of 2-1; (B) Co-crystal structure of compound 2-1 in CDK-2/cyclin A. (PDB ID: 2WIH, 2.5 Å). 
The kinase is depicted in yellow ribbons, and the hydrogen bonds are illustrated in blue dashed lines. 
Further exploration of Type-I TRK inhibitors was reported by Brasca et al.
143
 The group initially identified 
compound 2 as a potent CDK-2 (cyclin dependent kinase) inhibitor (Figure 5A).
143
 Enhancement in selectivity, 
antiproliferative activity, and optimization of the physiochemical and pharmacokinetic properties led to the identification 
of compound 2-1 (Milciclib, PHA-848125) (Figure 5A) with high potency (CDK-2 IC50 = 0.045 M) and high 
bioavailability (F = 85%). Serendipitously, this compound exhibited near equal potency against TRKA (IC50 = 0.053 M) 
with selectivity in the greater kinome (IC50s > 0.15 M).
143
 
Figure 5B illustrates the crystal structure of compound 2-1 in complex with CDK2/cyclin A.
143
 The compound 
binds in the ATP pocket of the kinase with the pyrazoloquinazoline ring system occupying the adenine region, while the 
phenyl moiety points toward the solvent accessible region. Compound 2-1 creates two hydrogen bonds with the protein 
backbone of the hinge with residue Leu83. The amide carbonyl group of 2-1 is within hydrogen bonding distance of the 
conserved lysine (Lys33).
143
 
Albanese et al. further evaluated the dual inhibitory activity of compound 2-1 against CDK-2 and TRKA.
144-145
 In 
vitro, 2-1 was able to inhibit NGF-induced phosphorylation of TRKA as well as downstream signaling in the DU-145 
human prostate carcinoma line. In vivo, 2-1 inhibited tumor growth in a human prostate DU-145 xenograft model in a 
dose dependent manner. Because of the dual inhibitory properties of 2-1, the compound shifts the paradigm for precision 
medicine. Instead of generating a ‘magic-bullet’ with high TRK kinase selectivity, Albanese et al. focused on validating 
and developing a ‘smart-bomb’ with activity on the oncogene lesion (TRK) paired with cell cycle inhibition (CDK).146 
 
 
 
 
 
Figure 6. (A) Identification of compound 3-1b; (B) Co-crystal structure of compound 3-1b with ALK (PDB ID: 2XBA, 
1.95 Å). The kinase is depicted in yellow ribbons, and the hydrogen bonds are illustrated in blue dashed lines. 
In line with developing TRK inhibitors with dual activity, Fancelli et al. identified a series of 5-phenylacetyl 
1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole as Aurora kinase inhibitors (compound 3, Aurora-A IC50 = 0.027 M) (Figure 
6A).
121
 Further medicinal chemistry efforts lead to the discovery of compound 3-1b. Compound 3-1b was found to have 
dual activity on TRKA (IC50 = 0.03 M) and Aurora A (IC50 = 0.013 M)
121
 with weak ALK (anaplastic lymphoma 
kinase) inhibitory activity (IC50 = 0.091 M).
147
 Akin to 2-1, compound 3-1b obtained dual activity on the oncogene 
lesion (TRKA) as well as cell cycle inhibition (Aurora A).
147
 
 
 
 
 
 
Figure 7. Structural optimization from compound 4 to 4-3. 
Recently, Menichincheri et al. disclosed research efforts to generate compound 4-3 (Entrectinib, RXDX-101) for 
ALK (IC50 = 0.012 M) (Figure 7).
148
 To develop ALK inhibitors from compound 4 (ALK IC50 = 0.073 M), the co-
crystal complex of ALK with compound 3-1b was studied (see Figure 6B).
148
 Analysis of the complex suggested that a 
mono-substitution at 2’-position would generate derivatives that occupy the ATP sugar pocket region while 
simultaneously displacing a water molecule. In addition, NH-R substituents at this position were able to stabilize the 
bioactive conformation through intramolecular hydrogen bonding. Based on this concept, different amines were attached 
to the 2’-position of the central phenyl ring.148 
The introduction of a primary amine at 2’ led to compound 4-1a with similar ALK potency (IC50 = 0.067 M).
148
 
This was consistent with modeling analysis as compound 4-1a lacked the substituent necessary to fill the sugar pocket. At 
R
1
, a methoxyethyl or methoxy propyl group generally led to a moderate loss in activity (4-1b, and 4-1c, ALK IC50 = 0.21 
M and 0.135 M, respectively) while a fluorine or a hydroxyl group increased activity (4-1d, and 4-1e , ALK IC50 = 
0.014 M and 0.026 M, respectively).148 On the contrary, phenyl or cyclohexyl significantly decreased affinity because 
of size constraints of the sugar pocket (4-1f, and 4-1g, ALK IC50 = 0.684 M and 0.56 M, respectively).
148
 Interestingly, 
introduction of a hydroxyl group furnished 4-1h of which the trans-isomer displayed 10-fold higher activity (ALK IC50= 
0.01 M) than the cis. When R1 is 4-amino-N-methylpiperidinyl (4-1i) or 4-aminotetrahydropyranyl (4-3), the resulting 
compounds exhibit excellent potency on ALK (IC50 = 0.015 and 0.012 M, respectively). The latter of the two had better 
cellular activity (Cell IC50 = 0.438 M vs 0.031 M), which might be due to a difference in cell permeability.
148
 
Introduction of a methyl group to R
2
 generated two enantiomers (4-2a), with one enantiomer being 3-fold more active 
than the other (ALK IC50= 0.059 M and 0.019 M, respectively, absolute configuration not determined).
148
 Due to labor-
intensive chiral separation and stability of the benzhydryl stereogenic center further development of these compounds was 
terminated. Strong electron withdrawing groups on the phenyl ring are crucial for ALK activity. Removing the 3,5-
difluoro substitution, changing the position of the fluorine, or replacing with methyl all decreased activity (Compounds 4-
2b to 4-2e, ALK IC50 = 0.106 M, 0.03 M, 0.038 M, 0.181 M, respectively).
148
 
 
 
 
 
After initial development for ALK, compound 4-3 was subsequently found active on ROS1 (IC50 = 0.007 M) 
and TRK (IC50s for TRKA/B/C were 0.001 M, 0.003 M and 0.005 M, respectively).
148-149
 In antiproliferative studies, 
compound 4-3 was active against the colorectal cancer cell line KM-12 (IC50= 0.0017 M) and also induced tumor 
stabilization (>90% TGI) when administered P.O. to mice bearing KM-12 xenografts.
150
 Compound 4-3 is currently in 
clinical trials for the treatment of patients with ALK-, ROS1- and TRK-dependent tumors and is exhibiting remarkable 
signs of efficacy.
148-149
 In a Phase 2 clinical trial, 4-3 is being investigated for advanced or metastatic solid tumors that 
harbor TRKA/B/C, ROS1, or ALK gene rearrangements (NCT02568267). 
 
Figure 8. (A) Co-crystal structure of compound 4-3 with ALK (PDB ID: 5FTO, 2.22 Å): (B) Co-crystal structure of 
compound 4-3 with TRKA (PDB ID: 5KVT, 2.45 Å). The kinase is depicted in yellow ribbons, and the hydrogen bonds 
are illustrated in blue dashed lines. 
The co-crystal structure of ALK with compound 4-3 was consistent with the above expectations (Figure 8A).
148
 A 
similar binding mode is observed in the co-crystal structure of 4-3 with TRKA (Figure 8B).
151
 The compound is anchored 
to the hinge through three hydrogen bonds between the aminoindazole moiety and the backbone of residues Glu590 and 
Met592 (Glu1197 and Met1199 in ALK). The difluorobenzyl-indazole core creates favorable contacts with Ala542, 
Leu657 (Leu1256, and Val1130 in ALK), and the gatekeeper Phe589 (Leu1196 in ALK).
148
 Moreover, the 3,5-
difluorobenzyl moiety is involved in multiple interactions with the backbone carbonyls of Asp668 from the DFG motif 
(Asn1254 and Gly1269 in ALK). The central phenyl ring makes a hydrophobic contact with Leu516 (Leu1122 in ALK); 
 
 
 
 
while the methylpiperazine is oriented towards the solvent front. In order to optimally fill the sugar pocket, the partially 
solvent-exposed tetrahydropyranyl moiety adopts a roughly orthogonal orientation with respect to the scaffold.
148
 
 
Figure 9. Structural optimization from compound 5 to 5-3. 
Another drug discovery campaign centered on ALK serendipitously uncovered 5-3 (Belizatinib, TSR-011), a 
novel, potent TRK inhibitor (Figure 9).
152
 Through HTS (high-throughput screening), Lewis et al. identified the ALK 
inhibitor 5 (ALK kinase IC50 = 0.003 M, pALK cell IC50 = 0.054 M; 64-fold, 103-fold, 15-fold selectivity over JAK2, 
SRC, and IGF1R, respectively),
152
 which was co-crystalized with ALK (Figure 10A).
152
 Through the benzoyl carbonyl 
oxygen and the benzimidazole NH, 5 was shown to bind to the hinge of ALK at Met1199 and the benzoyl ring was 
adjacent to the gatekeeper residue Leu1196. The cis-1,4 geometry of the cyclohexyl group pushes the methyl ester moiety 
into a hydrophobic pocket surrounded by Leu1256 and Gly1269. The piperidine moiety engages in Van der Waals 
interactions with two backbone carbonyls on the N-terminal lobe (Gly1121, Leu1122) in a shallow pocket on the surface 
of the protein at the entrance to the ATP binding pocket.
152
 
To improve cell potency, selectivity, and metabolic stability, SAR optimization was completed. First, the methyl 
ester was replaced with different esters and amides (compounds 5-1a to 5-1e). The isopropyl amide compound 5-1e 
displayed the best combination of activity and selectivity (ALK kinase IC50 = 0.002 M, pALK cell IC50 = 0.054 M; 
813-fold, 429-fold, 36-fold selectivity over JAK2, SRC, and IGF1R, respectively).
152
 To improve metabolic stability, a 
wide variety of modifications were investigated at the R
2
 position. Figure 9 depicts some of these modifications, and the 
tertiary alcohol analogue 5-3 appeared optimal. Finally, different substitutions were introduced to the 4-fluoro phenyl 
ring; however, these derivatives either decreased selectivity or suffered from compromised cellular activity against 
 
 
 
 
ALK.
152
 When screening 5-3 against a kinase panel, 5-3 was found to have potent pan-TRK activity (IC50 for TRKA/B/C 
< 0.003 M).153 Currently, 5-3 is under a Phase 1/2 study in patients with advanced solid tumors and lymphomas. 
(NCT02048488). 
 
 
Figure 10. (A) Co-crystal structure of compound 5 in ALK (PDB ID: 4FOC, 1.7 Å); (B) Co-crystal structure of compound 
5-3 in ALK (PDB ID: 4FOD, 2 Å). The kinase is depicted in yellow ribbons, and the hydrogen bonds are illustrated in 
blue dashed lines. 
The co-crystal structure of 5-3 with ALK (Figure 10B) shows that 5-3 binds similar to 5 (Figure 10A).
152
 
Compound 5-3 pushes into the active site of the kinase in a pocket formed by Val1180 and Leu1256, and is in close 
proximity to the gatekeeper residue Leu1196. The iminobenzamide moiety adopts the exocyclic acylimine tautomer 
permitting key hydrogen bonding interactions with the hinge region residue Met1199. This tautomer is favored by 
extended π-delocalization into the pendant aryl ring, achieved by retaining a coplanar arrangement between benzamide 
and benzimidazole moieties.
152
 
 
 
 
 
 
 
Figure 11. Structural optimization from compound 6 to 6-3. 
Isothiazole derivatives have been identified as TRK inhibitors (Figure 11). From an HTS campaign directed at 
TRKA, Lippa et al. identified compound 6 (TRKA IC50= 0.007 M).
154
 Initial SAR studies at R
1
 determined that 
substitution at the benzylic α-position remarkably influenced TKRA activity and VEGFR2 selectivity. Small aliphatic 
chains were well tolerated (6-1a, 6-1b, TRKA IC50s were 0.003 M and 0.004 M, respectively), while larger 
substitutions significantly diminished activity (6-1d, 6-1e , TRKA IC50s were 0.035 M and 2.6 M, respectively).
154
 The 
orientation of the R
1
 substitution also played a key role: the (R)-ethyl enantiomer 6-1b was >10-fold more active (TRKA 
IC50, 0.004 M vs 0.052 M) and was >100-fold more selective (VEGFG2 selectivity, 1,300X vs 10X) than the (S)-
enantiomer. SAR at R
2
 and R
3
 showed that substitution at these two positions are not necessary to maintain TRK activity 
(6-2a to 6-2d, TRKA IC50s were 0.01 M, 0.008 M, 0.105 M and 0.111 M, respectively).
154
 Further optimization 
identified that bicyclic moieties were important for TRK activity, especially the 7-membered ring system (compound 6-
2e , TRKA IC50< 0.001 M) and, consistent with previous data, the (R)-enantiomer was more active (6-3 vs 6-2f, TRKA 
IC50s were <0.001 M vs 0.091 M,). Compound 6-3 (Cpd5n) had pico-molar kinase potency and single-digit nanomolar 
activity against TRK-driven cell growth.
154
 
 
 
 
 
  
Figure 12. Co-crystal structure of compound 6-3 in TRKB (PDB ID: 4AT3, 1.77 Å). The kinase is depicted in yellow 
ribbons, and the hydrogen bonds are illustrated in blue dashed lines.  
The co-crystal complex of 6-3 in TRKB was obtained and is shown in Figure 12.
73
 The aliphatic portion of 6-3 is 
oriented towards the glycine-rich loop and exhibits clear, Type I binding.
73
 The glycine-rich loop forms a cage around the 
inhibitor and engages in strong, hydrophobic interactions through Phe565. The urea and amide groups on the thiazole bind 
to the hinge of TRKB, forming three hydrogen bonds. The benzo-cycloheptene group is sandwiched between the 
gatekeeper Phe633 and glycine-rich loop Phe565 side chains, likely contributing to the stabilization of the TRKB DFG-in 
conformation.
73
 This also explains the potency differences between the two enantiomers as the S-enantiomer could still 
bind the hinge but would clash with Phe565 due to difference in stereochemistry of the benzo-cycloheptene. The affinity 
of 6-3 for TRKB is also enhanced by several water-bridged hydrogen bonds between the inhibitor and the kinase.
73
 
 
 
 
 
 
Figure 13. Structural optimization from compound 7 to 7-3b. 
In another campaign to uncover novel TRK inhibitors, Choi et al. developed a series of substituted 
imidazopyridazine derivatives from compound 7 (TRKB IC50 = 0.083 M) (Figure 13).
155
 The crystal complex of 7 with 
TRKC (Figure 14A) shows that the ligand binds to the inactivated (DFG-out) form of the kinase and the 
imidazopyridazine warhead engages in a hydrogen bond at the hinge with Met620. The benzonitrile ring is wedged 
between Phe617 and Phe698, and the phenyl ring sits under the glycine-rich loop and faces the solvent front of the active 
site.
155
 
 Preliminary medicinal chemistry efforts focused SAR studies at R
1
 to R
4
, with the goal of identifying compounds 
with improved potency and pharmacokinetic properties suitable for in vivo profiling. Nitrile substitutions in the phenyl 
group (R
3
) at the 3- or 4-position were equally tolerated (7 vs 7-1a, TRKA cell IC50s = 0.85 M and 0.74 M). It was also 
observed that 3-substitution at the benzylamine phenyl ring (R
1
) led to a 10-fold increase in potency (7-1b, TRKA cell 
IC50 = 0.076 M).
155
 Modifying the phenyl ring (R
3
) with 3-F substitution at R
1
 furnished many tolerated functional 
groups that could either increase solubility or further drive potency (i.e. compound 7-1c, TRKA cell IC50 = 0.006 M). 
Methylation of the benzylic amine (R
3
) led to no significant change in potency indicating that the acidic proton on the 
benzylic amine does not hydrogen bond with TRK.
155
 Cyclizing the benzyl amine moiety with the adjacent phenyl ring 
was performed to rigidify the structure and reduce conformational entropy. The fused, five-membered ring system was 
optimal for TRK inhibition and exhibited a preference for the R-enantiomer (7-2a to 7-2e , TRKA cell IC50s = 0.17 M, 
0.075 M, 0.068 M, 3.13 M, and 0.021 M, respectively). Derivatization at R5 led to the discovery of the optimized 
compound 7-3b (GNF-8625).
155
 Compound 7-3b demonstrated potent, antiproliferative activity against TRK transfected 
Ba/F3 and KM-12 cell lines (IC50 = 0.001 M and 0.01 M, respectively). In a KM-12-derived tumor xenograft, 
compound 7-3b demonstrated antitumor efficacy in a dose dependent manner, inducing 20% tumor regression at a dose of 
50 mg/kg BID.
155
 
 
 
 
 
 
Figure 14. (A) Co-crystal structure of compound 7 in TRKC (PDB ID: 4YMJ, 2 Å); (B) Co-crystal structure of compound 
7-3a in TRKA (PDB ID: 4YNE, 2.02 Å). The kinase is depicted in yellow ribbons, and the hydrogen bonds are illustrated 
in blue dashed lines.  
Imidazopyridazines are frequently incorporated into kinase inhibitors as they readily form a hydrogen bond at the 
hinge with the C-6 carbon oriented towards the solvent.
156
 The warhead of 7-3a is based on imidazopyridazine and was 
expected to bind TRKA akin to 7. Surprisingly, the co-crystal structure of 7-3a with TRKA revealed an unexpected 180° 
rotation of the imidazopyridazine core at the hinge (Figure 14B).
155
 Only the (R)-enantiomer of 7-3a is active because the 
3-F-phenyl is optimally positioned downwards in the hydrophobic pocket. The moiety fills a pocket endogenously 
occupied by Phe669 and provides excellent shape complementary, likely contributing to increased affinity. Molecular 
modeling and crystallography studies indicated that two distinct binding modes exist (i.e. core flipping) with scaffold 7.
155
 
Based on the different TRK co-crystal structures obtained with 7 and 7-3a, it was concluded that the preferred binding 
mode depends on C-6 substitution. If the C-6 substitution is modified to (R)-phenylpyrrolidine, the “flipped” orientation is 
preferred as the pyrrolidine anchors the phenyl group in the hydrophobic pocket.
155
 The phenomenon of ‘core flipping’ 
could be employed to generate compounds with activity in multiple kinase families. Based on the crystal structure, 
compound 7-3a is a Type I kinase inhibitor. 
 
 
 
 
  
Figure 15. Chemical structures of compound 8, and second generation TRK inhibitors 9 and 10. 
Compound 8 (Larotrectinib, LOXO-101) is another selective, pan-TRK inhibitor exhibiting low nanomolar 
cellular potency against the TRK family (IC50 ranging from 0.002 M to 0.02 M) with 100-fold selectivity over other 
kinases (Figure 15).
49, 157
 The compound can induce cell-cycle arrest in the G1 phase and apoptosis in KM-12 cells.
49
 
Compound 8 is currently in a Phase 2, open-label study for patients with advanced solid tumors harboring a fusion of TRKA, 
TRKB, or TRKC (NCT02576431).
48
 The medicinal chemistry effort leading to the discovery of this compound and its co-
crystal complex with TRK have not been reported. However, because of the structure similarities between compounds 8 
and 7-3b, it can be inferred that 8 exhibits similar SAR properties to that of 7-3b. 
Second Generation Type I TRK Inhibitors 
All first generation TRK inhibitors exhibit profound, upfront efficacy but eventually lose effectiveness due to the 
development of secondary mutations in the TRK kinase domain. After treatment with 8 or 4-3 mutations in the TRK 
kinase domain have been reported,
158
 which renders further treatment ineffective.
47, 159
 These mutations include 
TRKA
G595R
 (and its paralogue TRKC
G623R
) in the solvent front of the active site, TRKA
G667C
 (and its paralogue 
TRKC
G696A
) adjacent to the DFG motif, and TRKA
F589L
 at the gatekeeper region.
47, 99, 159-161
 TRKA
G595R
 and TRKA
G667C
 
are analogous to ALK
G1202R
 and ALK
G1269A
, respectively.
159
 In TRKA, the native residues are important to accommodate 8 
and 4-3, while the mutations create steric clashes with the inhibitors. In addition, TRKA
G595R
 increases ATP affinity to the 
kinase.
159
 Structural modeling suggests that each mutation directly interferes with binding of 8, 4-3, and all other TRK 
tyrosine kinase inhibitors.
47, 160
 Functional studies have subsequently confirmed that cancer cells harboring these 
mutations are cross-resistant to all TKIs with anti-TRK activity.
162-163
 
 
 
 
 
 
Figure 16. (A) Proposed binding and steric interactions of 8 with the TRKA double mutant G595R and G667C, (B) 
Proposed binding of 9 to the TRKA double mutant; steric interactions are not predicted between G595R and G667C. The 
kinase is depicted in yellow ribbons.
164
 
To generate inhibitors that could overcome point mutations in TRK, compounds 9 (LOXO-195) and 24 (TPX-
0005) were designed to limit the compound surface area in the active site. (Figure 16). Both compounds were designed as 
fused macrocycles to reduce unnecessary interactions at either end of the binding pocket. Modelling suggested that 
TRKA
G595R
 would introduce steric clashes between the arginine side chain and the hydroxypyrrolidine group of 8, and 
TRKA
G667C
 would create steric clashes between the cysteine or alanine side chain and the diﬂuorophenyl group of 8 
(Figure E).
159
 To determine the impact of TRK kinase mutations on inhibitor activity, 8 and 9 were tested against 
TRKA
G595R
, TRKA
G667C
, and TRKC
G623R
. Compound 9 achieved low nanomolar inhibitory activity against all mutated 
kinase (IC50s = 0.002 M, 0.00098 M, and 0.0023 M); while compound 8 displayed significantly reduced inhibitory 
activity (IC50s = 0.069 M, 0.045 M, and 0.048 M).
159
 An innovative first-in-human clinical trial has demonstrated 
efficacy of compound 9 in 2 patients who had developed acquired resistance to 8 mediated by secondary TRKA
G595R
 or 
TRKA
G623R
 mutations.
159
 Compound 10, an analogue to 9, potently inhibited ROS1
G2032R
 (IC50 = 0.0084 M), TRKA
G595R
 
(IC50 = 0.0004 M), TRKB
G639R
 (IC50 = 0.0019 M) and TRKC
G623R
 (IC50 = 0.0004 M).
165
 10 also exhibited activity in 
xenograft tumor models bearing WT and kinase domain mutations of ALK, ROS1 and TRKA.
165-166
 
Other Type I TRK Inhibitors 
 
 
 
 
 
Figure 17. Chemical structures of other Type I TRK inhibitors 
Several other TRK scaffolds have been reported that exhibit Type I characteristics and are summarized in the 
following section (Figure 17). Aza-oxindole and oxindoles were reported as potent TRK inhibitors by Wood et al.
167
 The 
representative compound 11 exhibited pan-TRKA inhibitory activity (TRKA/B/C IC50s = 0.030 M, 0.007 M, 0.005 
M, respectively) with selectivity in the greater kinome but also inhibited VEGFR2 (vascular endothelial growth factor 
receptor 2).
167-168
 Compound 11 shares similarities in structure to other known VEGFR2 inhibitors, such as sunitinib, 
which likely accounts for its VEFGR2 profile.
167
 Choe et al. reported a series of pyrrole[3,4-c]pyrazole TRKA inhibitors 
(Figure 17). The representative compound 12 inhibits TRKA with an IC50 of 0.019 M. SAR studies indicated that the 
cyclopropyl and benzyl carbamate groups are essential for potency and removal of either resulted in a loss of activity.
169
 
Carboni et al. developed compound 13 as a dual IGF-1R/IR inhibitor (IC50 = 0.0018 M and 0.0017 M, respectively).  
Kinase profiling showed that compound 13 was active on several other kinases, including TRKA/B (IC50s = 0.007 M 
and 0.004 M, respectively).170 Cho et al. developed compound 14 as a c-MET inhibitor based on an aminopyridine core 
substituted with benzoxazole (IC50 = 0.08 M).
171
 Compound 14 was later identified to have activity against the mutant c-
MET
Y1230D
 kinase (IC50 = 0.003 M) and TRKA (IC50 = 0.039 M).
172
 Stachel et al. reported a series of pyrido[3,2-
d]pyrimidine as TRKA inhibitors; the representative compound 15 had a TRKA IC50 of 0.011 M and moderate cell 
activity (IC50=1.688 M).
173
 
Radiolabeled Type I TRK Inhibitors 
 
 
 
 
 
Figure 18. Chemical structures of representative radiolabeled Type I TRK Inhibitors. 
Positron emission tomography (PET) is a non-invasive in vivo imaging technique that enables the visualization 
and quantification of the distribution of molecules labeled with positron-emitting isotopes. This method enables the 
evaluation of biochemical and physiological processes by monitoring the distribution and kinetics of a labeled molecule in 
vivo, and has found broad application in clinical practice (personalized treatments), research, and pharmaceutical 
development.
174-177
 
Because of the clinical importance of TRK in cancer as well as the central nervous system, Bernard-Gauthier et al 
generated radiolabeled TRK ligands to assess and monitor TRKA/B/C levels in the brain. The TRK ligands were 
synthesized from known inhibitors using 
11
C- or 
18
F-labeled PET radiotracers suitable for in vivo imaging (compounds 16-
20) (Figure 18).
168, 178-182
 These compounds demonstrated comparable activity and selectivity profiles to the unlabeled 
precursor.
180
 Compound 16 displayed excellent TRK selectivity in a panel of brain and cancer relevant kinases and TRK-
specific binding in vitro in rat brain and human neuroblastoma cryosections. The radio-compound also exhibited uniform 
regional brain distribution but was highly susceptible to CYP450 metabolism.
168
 Nevertheless, TRK radio-compounds can 
prove instrumental in studying TRK biology, diagnosing TRK-positive disease, and determining drug disposition of TRK 
inhibitors in real time.
175, 177
 It is worth noting that compound 19 was the first TRK radiotracer clinical lead involved in a 
non-human primate imaging study;
182
 compound 20 was the first reported radiotracer used as an in vivo probe to explore 
endogenous kinase densities using PET neuroimaging in humans.
181
 
 
 
 
 
Type II TRK Inhibitors 
Type I TRK inhibitors are ATP competitive and typically possess pan-kinase activity. A method to increase 
kinase selectivity and potency is to generate inhibitors that bind in a Type II fashion.
183
 Type II inhibitors are generally 
more active against tyrosine kinases, which can be exploited to increase selectivity and potency profiles.
184
 TRK inhibitors 
that display Type II binding kinetics can be preferred depending on the biology being studied or the disease being treated. 
It is important to note that the most advanced TRK inhibitors in clinical trials are Type I (8 and 4-3). These inhibitors are 
being evaluated for anticancer properties and may have inhibition characteristics optimal for a tumor environment. In 
other therapeutic areas, such as the central nervous system (CNS) or pain management, TRK inhibitors with a Type II 
profile maybe preferred because, as a class, they are more selective than Type I inhibitors.
184
 However, the typically larger 
molecular architecture of Type II compounds can cause less favorable drug-like properties, leading to development 
challenges. In the following section, the development of Type II TRK inhibitors is disclosed, and developmental efforts 
were primarily focused on optimizing for anticancer properties. 
 
Figure 19. Structural optimization from compound 21 to 21-3b (GNF-5837). 
Albaugh et al identified Type II TRK inhibitors based on an oxindole-core (Figure 19).
185
 Oxindole 21 inhibited 
Ba/F3-Tel-TRKA/B/C with IC50s less than 0.06 M. SAR studies at the R
1
 position showed that the phenyl ring is critical 
for TRK specific inhibitory activity (21-1a vs 21-1b, TRKA cell IC50: 2.3 M vs 0.91 M).
185
 To improve drug properties, 
 
 
 
 
several basic groups were introduced at the terminal phenyl ring and were well tolerated and increased potency, but did 
not improve solubility. Substituting the aryl ring with 3-CF3 at R
1
 is crucial for TRK activity (21-1c and 21-1d, TRKA 
cell IC50: 0.39 M and 0.013 M 0.39 M, respectively). Truncating the amide group to aniline resulted in a total loss of 
activity, indicating the amide is necessary for TRK activity (21-1e , TRKA cell IC50> 10 M).
185
 Replacement of the 
pyrrole with other groups or methylation of the pyrrole nitrogen yielded significantly less potent compounds suggesting 
that the acidic proton on pyrrole is involved in a key hydrogen bond at the hinge region. Substitution on the pyrrole 
showed that carbolic acid at position 4 is preferred for potency and selectivity, with or without methyl substitution (21-2a 
to 21-2c, TRKA cell IC50: 0.014 M, 0.01 M, and 0.012 M; selectivity: 43-fold, 150-fold and 108-fold, respectively).
185
 
Replacement of the amide with urea generated compounds with increased potency and selectivity over VEGFR2 (21-3a, 
TRKA cell IC50= 0.004 M, selectivity 130-fold).
185
 Introduction of a methyl substitution at R
3
 and a fluorine at R
4
 
generated compound 21-3b (GNF-5837), which exhibits pan-TRK inhibition (TRKA/B/C IC50s = 0.011µM, 0.009µM, 
0.007 µM, respectively) and about 300-fold selectivity over VEGFR2 (IC50 = 3.0 µM). In BALB/c mice and Sprague–
Dawley rats, compound 21-3b demonstrated low drug clearance and moderate bioavailability. In mice bearing RIE 
xenografts expressing TRKA and NGF, compound 21-3b (100 mg/kg/d P.O.) significantly inhibited tumor growth.
185
 
 
Figure 20. Co-crystal structure of compound 21-3a in TRKC (PDB ID: 3V5Q, 2.2 Å). The kinase is depicted in yellow 
ribbons, and the hydrogen bonds are illustrated in blue dashed lines.  
In the co-crystal structure of 21-3a with TRKC (Figure 20), 21-3a is found to bind to the kinase in a Type II 
manner.
185
 The oxindole core and pyrrole nitrogen form key hydrogen bonds with hinge residues Glu618, Tyr619, and 
Met620. The urea functionality interacts with Glu588 from the α-C-helix and Asp697 from the DFG motif. In addition, 
 
 
 
 
interactions occur at the phenyl bridge with Phe617 (gatekeeper) and a face to edge interaction with Phe698 from the DFG 
motif.
185
 
 
Figure 21. (A) Structural optimization from compound 22 to 22-3; (B) Co-crystal structure of compound 22-3 with TRKA 
(PDB ID: 5JFX, 1.63 Å). The kinase is depicted in yellow ribbons , and the hydrogen bonds are illustrated in blue dashed 
lines.  
 
Skerratt et al. reported a series of pyrrolopyrimidine derivatives as pan-TRK inhibitors (Figure 21A).
186
 By 
employing a high-throughput TRKA/B cell screening assay, compound 22 was identified as a pan-TRK inhibitor 
(TRKA/B/C IC50s = 0.002 M, 0.005 M, and 0.004 M, respectively) with strong kinome selectivity but poor water 
solubility (< 0.3 M).186 To improve solubility, the urea group was replaced with an amide and the 4-NH2 was removed to 
generate compound 22-1 (TRKA/B/C IC50s = 0.012 M, 0.004 M, and 0.003 M, respectively) with improved water 
solubility (~13.2 M).186 It was determined that the scaffold was likely metabolized by aldehyde oxidase and inhibited 
hERG (human Ether-à-go-go-Related Gene) potassium heart channels.
187-188
 In order to reduce metabolic liabilities and off 
target toxicities, an amino group was added at the 2-position furnishing compound 22-2 (TRKA/B/C IC50s = 0.008 M, 
0.005 M, and 0.004 M, respectively; solubility = 30 M).186 To further improve physical-chemical properties and 
aqueous solubility, a hydrophilic hydroxymethylene group was added to N-
i
Pr motif and the terminal ring was replaced 
with pyridine to obtain compound 22-3 (PF-06273340). Compound 22-3 was a potent pan-TRK inhibitor (TRKA/B/C 
 
 
 
 
IC50s = 0.006 M, 0.004 M, and 0.003 M, respectively; solubility= 131 M) and exhibited selectivity over a large 
kinase panel.
186
 Currently, Phase 1 clinical trials are ongoing to examine the activity of different doses of 22-3 on a panel 
of evoked pain tests in healthy male subjects (NCT02260947). 
 Figure 21B shows the co-crystal structure of 22-3 bound to TRKA and highlights key protein−ligand 
interactions.
186
 Compound 22-3 binds to the DFG-out form of TRK, with the 2-aminopyrrolopyrimidine forming 
hydrogen bonds at the hinge and the ketone binding to Glu590 through a water contact.
186
 Most kinase inhibitors engage 
in one or two interactions at the hinge, while 22-3 is found to engage in three. The central pyridine group of 22-3 engages 
in a double π-π stacking interaction with Phe589 (gatekeeper residue) and Phe669 (DFG motif).  The carbonyl oxygen 
forms a hydrogen bond with the amide backbone of Asp668 (DFG motif) and the amide engages TRKA through a water 
contact between Lys544 and Glu560 from the c-Helix. The lipophilic back pocket accommodates the chloropyridine 
group.
186
 Based on the binding characteristics of 22-3, the inhibitor can be considered Type II. 
 
 
Figure 22. (A) Chemical structures of representative dicarboxamide TRKA inhibitors; (B) Co-crystal structure of 
compound 26 in c-MET (PDB ID: 5DG5, 2.6 Å). The kinase is depicted in yellow ribbons, and the hydrogen bonds are 
illustrated in blue dashed lines.  
Compound 23 (Cabozantinib, XL184) is a multiple kinase inhibitor with activity against c-MET/VEGFR2 and 
was found to have a potent TRKB inhibitory activity (IC50 < 0.02 M) (Figure 22A).
189
 Compound 23 is currently under 
Phase 2 clinical trials in patients with RET fusion-gene non-small cell lung cancer and those with other activating genes, 
 
 
 
 
such as ROS1, NTRK, MET or AXL (NCT01639508). Compound 24 (Sitravatinib, MGCD516) was developed by 
Patwardhan et al. as a potent multi-kinase inhibitor (Figure 22A) active against several kinases (IC50s for AXL: 0.0015 
M, VEGFR2: 0.005 M, FLT3: 0.008 M, c-KIT: 0.006 M, TRKA: 0.005 M, and TRKB: 0.009 M). Compound 24 
blocked phosphorylation of several RTKs and induced potent anticancer effects in vitro; the compound was also active in 
vivo in MPNST (neurosarcoma) and LS141 (hybridoma) mouse xenograft models.
190
 Compound 24 is currently under 
Phase 1 clinical development for patients with advanced solid tumor malignancies (NCT02219711). Compound 25 
(Altiratinib, DCC2701) was reported by Smith et al. as a multi-targeted kinase inhibitor with preferential activity on 
MET, TIE-2, and VEGFR2 (IC50s = 0.0027 M, 0.008 M, and 0.0092 M, respectively) (Figure 22A). Subsequently, 25 
was identified to exhibit activity as a pan-TRK inhibitor (TRKA/B/C IC50s = 0.00085 M, 0.0046 M, and 0.0083 M, 
respectively) and FLT3 inhibitor (IC50 0.0093 M).
191
 In cell antiproliferative assays, compound 25 exhibited IC50s of 
0.00069 M in K562 cells, 0.0012 M in SK-N-SH cells, and 0.0014 M in KM-12 cells. Compound 25 inhibited tumor 
growth in the MET-amplified MKN-45 xenograft model in a dose-dependent manner. Further, compound 25 can actively 
penetrate the blood-brain-barrier, indicating its potential for the treatment of brain cancers, brain metastases, and cancer 
pain. Compound 25 is currently under Phase 1 clinical development for patients with advanced solid tumors with NTRK 
or MET genomic alterations (NCT02228811). 
Figure 22B illustrates the general Type II binding mode of the dicarboxamide kinase inhibitor class.
191
 The 
pyridine of 26 (DP4157) binds to the hinge region and forms a hydrogen bond with Met1160. The central di-fluoro phenyl 
ring is in a hydrophobic pocket formed by Lys1110, Leu1157 and Phe1223, and engages in a π-π stacking interaction with 
Phe1223. The terminal para-fluoro phenyl ring binds in the allosteric pocket between the DFG motif and α-C-helix.191 
Other Type II TRK Inhibitors 
 
 
 
 
 
Figure 23. Chemical structures of other Type II TRK inhibitors 
El-Damasy et al. reported benzothiazole derivative 27 as multi-targeted kinase inhibitors (Figure 23).
192
 
Compound 27 was active on several kinases with IC50 values below 0.1 M (including VEGFR2, ABL, TRKA, TRKB, 
and TIE2 et al.). Specifically, the IC50s for TRKA and TRKB were 0.0038 M and 0.0044 M, respectively. In 
antiproliferative studies, compound 27 was active against the KM-12 cell line with an IC50 of 0.019 M. Arcari et al. 
reported a series of 4-aminopyrrolopyrimidine derivatives as TIE-2 inhibitors.
193
 Compound 28 (Figure 23) was identified 
as a potent, pan kinase inhibitor with activity against c-MET (IC50 = 0.0047 M) and RON (IC50 = 0.0012 M) and 
exhibited anti-tumor activities in multiple mouse xenograft models.
157
 Medicinal chemistry efforts led to the identification 
of compound 29 (Figure 23), which was found to be a TIE-2/TRKA dual inhibitor (IC50 for TIE-2 and TRKA were 0.0037 
M and 0.004 M, respectively).193 A close analogue of 29, compound 30, progressed to clinical trials, but the Phase I 
multiple dose trials were terminated due to the development of significant CNS adverse events, including cognitive 
deficits, personality changes, and sleep disturbances.
28, 186
 Compound 31 (Figure 23) is another compound reported by 
Stachel et al.
173
 with good TRK inhibitory activity (TRKA IC50 = 0.009 M, cell IC50 = 0.007 M). This compound was 
found to bind to the TRK kinase in the DFG-out conformation.
194
 On compound 31, the imidazole warhead binds to the 
hinge region, the central triazole ring forms an interaction with the gatekeeper residue, and the pyrazole occupies a 
 
 
 
 
selectivity pocket normally occupied by Phe669. This inhibitor is very unique because of the innovative triazole linker 
and imidazole warhead. Frett et al described pyrazine-based derivatives as TRKA inhibitors (Figure 23).
195
 Compound 32 
had a TRKA IC50 of 0.005 M (Figure 23), and modeling studies determined the compound binds in a typical Type II 
conformation. Compound 33 was initially reported by Conway et al. as a selective CSF-1R (colony stimulating factor 1 
receptor) inhibitor (Figure 23), which completely inhibited CSF-1R in vitro at an IC50 of 0.06 M but was inactive against 
26 other kinases.
196
 Later, the same authors found compound 33 also inhibited TRKA with an IC50 of 0.88 M.
197
.The 
radiolabeled analogue of 33 was reported by Bernard-Gauthier et al.
180
 Bertrand et al. reported that compound 33 bound 
to TRKB in a DFG-out conformation.
73
 Hong et al. reported a series of 3,5-disubstituted-7-azaindoles as TRK 
Inhibitors.
198
 Further modification uncovered compound 34 (Figure 23), which is a pan-TRK inhibitor with selectivity 
over 30 kinases. The activity of compound 34 against TRK isoforms was equal (pan-TRK IC50 = ~0.001 M), but was 
100-fold more selective against other kinases. 
198
 Amino pyrimidine derivatives were developed as TIE-2 (tunica interna 
endothelial-2) inhibitors with compound 35 (Figure 23) exhibiting TIE-2 inhibition (IC50 = 0.005 M) with almost equal 
TRKA inhibitory activity (IC50 = 0.008 M).
199
 Through screening of an in-house kinase library, Kim et al. found 2-
amino-5-(thioaryl)thiazole to be a promising scaffold for TRK inhibition.
108
 Further SAR investigation led to the 
identification of compound 36 (Figure 23) (TRKA IC50 = 0.0006 M), which was selective over CDK, MET, and IGF-1R 
(IC50s = 0.54 M, >1 M, and 0.43 M, respectively). 
Pseudo-Type II TRK Inhibitors 
 
 
 
 
 
 
Figure 24. (A) Identification of compound 37-1; (B) Co-crystal structure of compound 37 and its binding mode in TRKA 
(PDB ID: 4PMP, 1.8 Å). The kinase is depicted in yellow ribbons, and the hydrogen bonds are illustrated in blue dashed 
lines.  
A quintessential property of Type II inhibitors is the formation of a strong hydrogen bond at the hinge region.
137
 
In certain inhibitors of TRK, however, the hydrogen bond at the hinge is abnormally weak with the majority of important 
interactions occurring in an adjacent allosteric pocket. This was first reported by Stachel et al. with the development of 
urea based compound 37 (Figure 24A) (TRKA kinase IC50 = 4.233 M, cell IC50 = 0.549 M).
173
 Structure optimization 
resulted in the identification of compound 37-1 (TRKA kinase IC50 = 0.011 M, cell IC50 = 0.003 M). Figure 24B 
illustrates the binding mode of 37 with TRKA.
173
 It is clear from this study that the compound bound to =TRKA in a 
DFG-out conformation, which is a typical feature for amide- and urea-linked Type II kinase inhibitors. However, 37 is 
structurally unlike any known Type II TRK inhibitor because of its low molecular weight and simple architecture.
173
 At 
the ATP-binding site, the thiazole heterocycle forms a very weak hydrogen bond (3.45 Å) with the amide backbone of 
Met592. The benzylic ring is involved in hydrophobic interactions with the gatekeeper residue, Phe589. The para-
trifluoromethoxyphenyl group occupies the hydrophobic pocket normally occupied by Phe669 in the DFG-in 
conformation. The amide carbonyl forms a hydrogen bond with Asp668 as is typical with most Type II kinase 
inhibitors.
137
 A highly unique attribute to 37 is the cyclopropyl group, which occupies a hydrophobic cleft and is tucked 
 
 
 
 
against Val524. This is an uncommon trait, as most kinase inhibitors are unsubstituted at this position and hydrogen bond 
to a glutamic acid on the α-C-helix.173 One interpretation of the cyclopropyl SAR is that a critical hydrophobic mass is 
required to fill a small pocket near Val524 and Phe589. The placement of a hydrophobic group at this region is 
hypothesized to displace water, which would otherwise occupy the area.
173
 These interactions suggest the compound 
exhibits binding properties more typical of a Type III inhibitor. 
 
 
Figure 25. (A) Identification of compound 38-1; (B) Co-crystal structure of compound 38 and its binding mode in TRKA 
(PDB ID: 4PMS, 2.8 Å). The kinase is depicted in yellow ribbons and the hydrogen bonds are illustrated in blue dashed 
lines.  
In the same manuscript by Stachel et al., the author discussed the development of compound 38 (TRKA kinase 
IC50 = 17.13 M, cell IC50 = 1.162 M) to compound 38-1 (TRKA kinase IC50 = 0.051 M, cell IC50 = 0.029 M) (Figure 
25A).
173
 Compound 38 was shown to bind to the DFG-out conformation of TRKA (Figure 25B).
173
 The co-crystal 
structure revealed several unusual binding features. First, no direct interaction between the hinge backbone and the 
inhibitor was identified. Instead, the N5 nitrogen from the azaindole was shown to participate in a water-mediated 
hydrogen bond to the hinge region.
173
 The naphthalene moiety was buried in the hydrophobic cleft at the front of the hinge 
 
 
 
 
flanked by the activation loop residue Met671. One of the more unusual binding features is that the indole carboxylic acid 
interacts with two backbone amides in the activation loop. The unique interactions at the hinge and the activation loop 
regions anchor 38 to the ATP binding site. A third interaction was also evident between the carboxylic acid and Lys544 
on the roof of the ATP binding pocket.
173
 Compound 38 exhibited phosphorylation-dependent binding, which was due to 
the unusual conformation between the indole carboxylic acid and the activation loop. In the co-crystal structure, Tyr676 
was involved in a hydrogen-bond interaction with Asp596. Since Tyr676 is a known phosphorylation site on TRKA, 
phospho-Tyr676 would disrupt this interaction with Asp596, forcing the activation loop away from the active site and 
stabilizing the active conformation. As such, the phosphorylated form of the enzyme is not able to bind compound 38.
173
 
Because of the highly unique binding of 38 to TRKA, the compound exhibits a profile more typical of Type III. 
Type III-JM TRK Inhibitors  
TRKA activation triggers intracellular signaling cascades that increase the sensitivity of nociceptors, thus leading 
to chronic sensitization and pain.
200
 However, TRKA/B/C share significant sequence homology at the kinase domain, 
which will make it extremely difficult to develop inhibitors selective for a single isoform. A method to circumvent 
selectivity issues is to develop allosteric inhibitors that do not bind to the highly conserved ATP active site. In an effort to 
identify TRKA specific inhibitors, Su et al. discovered compounds with novel scaffolds that bound to the juxtamembrane 
(JM) domain of TRKA.
138
 The JM domain is located between the kinase domain and the transmembrane domain, and 
there is only 36% identity between TRKA and TRKB and 40% identity between TRKA and TRKC.
138
 These findings 
provide the research community with a novel, exploitable region to generate TRK selective small molecule inhibitors. 
 
 
 
 
 
Figure 26. (A) Chemical structure of compound 39; (B) Co-crystal structure of compound 39 in the allosteric pocket of 
TRKA (PDB ID: 5KMI, 1.87 Å); (C) Interactions of compound 39 with surrounding residues. The kinase is depicted in 
yellow ribbons and the hydrogen bonds are illustrated in blue dashed lines.  
Compound 39 is a selective TRKA inhibitor (IC50s for TRKA/B/C were 0.099 M, > 81 M and 25 M, 
respectively) (Figure 26A).
138
 In the co-crystal structure of 39 and TRKA (Figure 26B and Figure 26C), compound 36 
bound behind the DFG motif opposite of the kinase active site.
138
 The DFG motif was found in a DFG-out, inactive 
conformation, with Phe669 pointed toward the active site. Asp668, which coordinates to the phosphate groups on ATP, is 
away from the active site in the structure. The central urea of compound 39 makes two hydrogen bonds with Asp668. 
Asp668 is part of the DFG motif, and binding to compound 39 requires the DFG motif to be in the ‘out’ conformation.138 
The fluorine moiety of compound 39 occupies a relatively hydrophobic pocket formed primarily by aliphatic amino acids. 
The structure clearly reveals interactions at the JM region. Ile490, within the JM, sits on top of the fluorine moiety, aidin g 
to the formation of the hydrophobic pocket 
138
 Similar to other TRKA co-crystal kinase structures, there is a shift in 
Phe646, which creates a pocket to accommodate the fluorine. The oxygen of the central urea in compound 39 forms a 
hydrogen bond with the amide nitrogen of Ile490. The phenyl moiety occupies a position between Lys544 of the β3 strand 
and Glu560 of the α-C-Helix.138  
 
 
 
 
 
Figure 27. (A) Chemical structure of compound 40; Co-crystal structure of compound 40 in the allosteric pocket of TRKA 
(PDB ID: 5KMK, 1.65 Å). (C) Interactions of compound 40 with surrounding residues. The kinase is depicted in yellow 
ribbons and the hydrogen bonds are illustrated in blue dashed lines.  
Compound 40 is another selective TRKA inhibitor with interesting binding features (IC50s for TRKA/B/C were 
3.3 M, >81.0 M, and 27 M, respectively) (Figure 27A).138 The co-crystal structure of compound 40 revealed the 
compound bound to the same pocket as 39, behind the DFG motif (Figure 27B and Figure 27C). The trifluorophenyl 
moiety of 40 sits in the pocket occupied by the fluorine of compound 39. The central amide nitrogen is positioned close to 
the carboxylic acid of Asp668. The binding site is quite similar between the two structures except for the following 
differences: (1) for compound 39, Ile490 packs above the phenyl ring, but Leu486 packs above the phenyl ring for 40; (2) 
for 39, Phe646 was displaced by the bulky moiety in the hydrophobic pocket, but for 40, the smaller moiety 
accommodates Phe646 in a position closer to the active conformation.
138
 
 
Figure 28. (A) Chemical structure of compound 41; (B) Co-crystal structure of 41 bound in the allosteric pocket of TRKA 
(PDB ID: 5H3Q, 2.1 Å); (C) Interactions of compound 41 with surrounding residues. The kinase is depicted in yellow 
ribbons and the hydrogen bonds are illustrated in blue dashed lines.  
A similar finding was also disclosed by Furuya et al.
200
 Compound 41 (Figure 28A) showed potent inhibitory 
activity against TRKA (IC50 = 0.0027 M) but was selective against TRKB and TRKC (IC50s were 1.3 M and 2.5 M, 
respectively). Figure 28B and Figure 28C illustrate that compound 41 bound to the JM region of TRKA. The 
 
 
 
 
configuration of the kinase domain and A loop is very similar to that observed for Apo TRKA.
200
 41 binds to the deep 
pocket formed by the DFG region of the A loop, glycine-rich loop (G loop), C-helix, and JM region. This pocket is 
completely separate from the ATP site. There are four key interactions that 41 creates at the binding region: (1) Asp668 of 
the DFG motif forms two hydrogen bonds with the urea moiety; (2) His489 interacts with the pyrazole ring via π-π 
interactions and with the ethoxy group via CH-π interactions; (3) Ile490 forms a hydrogen bond with the urea moiety and 
interacts with the difluorobenzene group of 41 via CH-π interactions; (4) His648 interacts with the difluorobenzene 
moiety through a π-π stacking interaction.200 In addition to these, Leu486 is also involved in weak Van der Waals 
interactions with the methyl and ethoxyl groups of 41. Interestingly, these amino acid residues are not conserved in TRKB 
nor TRKC but are integral for high binding affinity in TRKA.
200
 Further exploitation of these TRKA specific amino acids 
could furnish numerous allosteric scaffolds with high TRKA selectivity. 
 
 
Figure 29. (A) Chemical structures of compounds 42, 43, and 44; (B) Co-crystal structure of compound 44 bound to the 
allosteric pocket of TRKA (PDB ID: 6D20, 1.94 Å); (C) Interactions of compound 44 with surrounding residues. The 
kinase is depicted in yellow ribbons and the hydrogen bonds are illustrated in blue dashed lines.  
 
 
 
 
Recently, Bagal et al. reported the discovery of a series of N-phenyl-pyrazole based compounds as selective 
TRKA inhibitors (Figure 29A).
201
 The original hit 42 showed moderate TRKA inhibitory activity (TRKA cell IC50 = 3.3 
M) and >10-fold selective over TRKB/C (TRKB/C cell IC50s > 50 M). By introducing an amino-pyridine ring to the 
dichloro-phenyl ring and switching the methyl to an amide group, the resultant compound 43 demonstrated 66-fold 
improvement in TRKA potency (cell IC50 = 0.05 M) and was >80-fold selective over TRKB/C (Cell IC50s were 14 M 
and 4.1 M, respectively) with improved drug-like properties.186 A variety of functional groups were evaluated on the 
pyridine and central phenyl ring, which led to the identification of 44 (TRKA/B/C IC50s = 0.01 M, 1.8 M, and 0.7 M, 
respectively) (Figure 29A). Compound 44 showed <15% inhibition against a panel of over 390 kinases at a concentration 
of 10 M and was 72% orally bioavailable.201 Figure 29B and Figure 29C illustrate the binding mode of 44 in the 
allosteric pocket of TRKA. The pyridyl nitrogen forms a hydrogen bond with the backbone of Asp668. The di-chloro 
central phenyl ring occupies the lipophilic pocket surrounded by Leu486, Ile572, Phe646 and Ile666. The terminal 
carbonyl group interacts with the side chain of Arg673 and the tertiary alcohol is exposed to the solvent front.
201
 
 
 
 
 
 
Figure 30. (A) Chemical structures of compounds 45 and 46; (B) Co-crystal structure of compound 45 binding in the 
allosteric pocket of TRKA (PDB ID: 5KMM, 2.1 Å); (C) Interactions of compound 45 with surrounding residues; (D) Co-
crystal structure of compound 46 in the active site of TRKA (PDB ID: 5KMO, 2.7 Å). The kinase is depicted in yellow 
ribbons and the hydrogen bonds are illustrated in blue dashed lines.  
However, it is worth noting that two analogues of 39, compounds 45 and 46 (by switching the fluorine moiety to 
naphthalene or pyridine), were also reported by Su et al. (Figure 30A).
138
 These two compounds were active against 
TRKA and TRKC (45, TRKA/C IC50s = 4.1 M and 7.1 M, respectively; 46, TRKA/C IC50s = 4.0 M and 2.3 M, 
respectively). Interactions of compound 45 with the kinase domain are similar to 39 but the JM interactions are altered as 
His489 is shifted away from to the compound (Figure 30B and Figure 30C). Instead of binding to the allosteric pocket, 46 
binds to the active site in an atypical Type I conformation (Figure 30D). The urea carbonyl group forms a hydrogen bond 
with the hinge residue Met592, and the pyridine fragment has a weak π-π interaction with the DFG motif residue 
Phe669.
138
 In this case, it is still uncertain whether compounds with such scaffolds will exhibit TRKA selectivity. It could 
be expected that only a subset of Type III inhibitors could be TRKA-selective because specific JM domain interactions 
are required for inhibition.
133
 
Beyond compounds described above, there are three additional TRK inhibitors under clinical development with 
structures that have not been disclosed. These compounds include PLX7486 (NCT01804530), DS-6051B 
(NCT02279433), and F17752 (2013–003009–24). 
Clinical Evaluation of TRK Inhibitors 
Table 2. Reported drugs under clinical trials with known inhibitory activity of TRK kinases 
NCT Identifier Phase Therapeutic Agent  Indication Status Patient Selection Estimated Completion 
NCT03213704 Phase II Larotrectinib (8) Pediatric Cancers Recruiting NTRK gene fusions 09/2024 
NCT02637687 Phase II Larotrectinib (8) CNS Cancers Recruiting / 06/2019 
NCT02576431 Phase II Larotrectinib (8) NTRK+ Solid Tumors Recruiting NTRK gene fusions 04/2018 
NCT02122913 Phase I Larotrectinib (8) Solid Tumors Recruiting NTRK gene fusions 02/2017 
NCT03215511 Phase I/II LOXO-195 (9) TRK Resistant  Tumors Recruiting TRK-resistant lesions 08/2019 
NCT02568267 Phase II Entrectinib (4-3) Solid Tumors Recruiting NTRK, ROS1, or ALK  10/2019 
 
 
 
 
gene rearrangements 
NCT02097810 Phase I Entrectinib (4-3) 
Advanced/Metastatic 
Cancer 
Active 
NTRK, ROS1, or ALK  
molecular alterations 
06/2019 
NCT02650401 Phase I Entrectinib (4-3) 
Pediatric and CNS 
Cancers 
Recruiting 
With or without NTRK, ROS1, or ALK gene 
fusions 
08/2018 
NCT01639508 Phase II Cabozantinib (23) Advanced NSCLC Recruiting 
RET, ROS1, or NTRK fusions  
or increased MET or AXL activity 
07/2019 
NCT02048488 Phase I/IIa Belizatinib (5-3) 
Solid Tumors and 
Lymphomas 
Unknown / 09/2016
+
 
NCT02279433 Phase I DS-6051b Advanced Solid Tumors Active NTRK or ROS1 gene rearrangements 11/2019 
NCT02675491 Phase I DS-6051b Advanced Solid Tumors Active NTRK or ROS1 gene rearrangements 09/2018 
NCT02219711 Phase I Sitravatinib (24) Advanced Cancers Recruiting 
MET, NTRK, or DDR2 mutations,  
MET or KIT/PDGFRA/VEGFR2 gene 
amplification,  
MET, RET, AXL, NTRK1, or NTRK3 gene 
rearrangements,  
or CBL gene function mutations loss 
12/2018 
NCT01804530 Phase I PLX7486 Advanced Solid Tumors Terminated NTRK point or fusion mutations 01/2018* 
NCT02228811 Phase I Altiratinib (25) Advanced Solid Tumors Terminated NTRK or MET gene alterations 11/2017* 
+ Study has passed its completion date and status has not been verified in more than two years 
*Actual Primary Completion Date 
 
 All TRK-directed compounds under clinical investigation are pan-TRK inhibitors. This is likely due to the 
conservation of amino acids at the ATP binding domain of TRK isoforms. Pivotal TRK structural analysis completed by 
Bertrand, et al. only identified a two amino acid difference between the ATP binding site of TRKA and TRKB.
73
 When 
analyzing TRKB and TRKC, all ATP binding site residues were identical.
73
 Because all TRK inhibitors in clinical trials 
elicit activity by binding at the ATP binding site, they all possess pan-TRK activity. This activity profile is possibly 
beneficial because the inhibitors, in theory, can be utilized against a broad spectrum of tumors.  However, this must be 
vetted cautiously, as dose-limiting toxicity can also increase based on inhibition profiles. An extensive, clinical overview 
for the development of TRK inhibitors has been reviewed by Lange, et al.
202
 
 Larotrectinib (8, LOXO-101) is under clinical investigation to treat melanoma, glioblastoma, NSCLC, pancreatic 
and ovarian cancers, and pediatric cancers. Following a single, oral dose, the unbound plasma concentration of 
 
 
 
 
larotrectinib is sufficient to inhibit TRKA/B/C signaling without substantial inhibition of other kinases.
203
 In a phase I 
study with larotrectinib, six patients with NTRK fusions with heavily pretreated advanced disease were enrolled 
(NCT02122913).
204
 Of the six patients, three had partial responses within 3-4 months and one patient had a near-complete 
response after 8 months.
157
 The drug was well tolerated, and the main side effects were fatigue, dizziness, and anemia. 
Larotrectinib was even well tolerated and efficacious in pediatric carcinomas harboring a TRK oncogene.
205-206
 Due to the 
overall positive results of the phase I study, Bayer and Loxo Oncology initiated a multicenter phase II basket trial to 
evaluate larotrectinib in patients with an NTRK fusion oncogene (NCT02637687 and NCT02576431). The overall 
response rate to treatment was 75%, with 13% exhibiting a complete response.
99
 At 1 year, 55% of the treated patients 
remained progression free. Based on the phase II results, larotrectinib has marked and durable antitumor efficacy in 
patients with NTRK fusions, regardless of age or tumor origin.
99, 207
 Meeting future endpoints of clinical trials, such as 
median duration of response, progression-free survival, and overall survival, will further confirm the clinical utility of 
larotrectinib. 
 Entrectinib (4-3, RXDX-101) is a pan-kinase inhibitor under clinical development by Ignyta with activity against 
TRKA/B/C, ROS1, and ALK fusion oncogenes.
149
 In a phase 1 clinical trial, 119 patients were treated with entrectinib 
split between two subgroups: ALKA-372-001, 54 patients, and STARTRK-1, 65 patients (NCT02097810).
208
 Entrectinib 
was shown to be well tolerated and efficacious against NTRK1/2/3 and ALK gene fusions, including patients with primary 
or secondary CNS disease.
208
 The majority of treatment related toxicities were Grades 1-2 and reversible with cessation or 
modification of treatment.
208
 In particular, responses were achieved regardless of histology, with responses observed in 
NSCLC, MASC, melanoma, glioneuronal tumor, colorectal cancer, and RCC.
208
 Response rates were highest in NTRK-
rearranged tumors, which provided first-time, clinical ‘proof-of-concept’ that NTRK-rearrangements are actionable drivers 
of tumor growth.
208
 Because of the success of phase 1 studies, a global, multicenter phase II basket study (STARTRK-2) 
is currently recruiting patients with NTRK-, ROS1-, and ALK-rearranged tumors (NCT02568267).
209
 These studies are 
being performed to confirm the results of the phase 1 study and to further establish the safety profile of entrectinib in a 
larger patient population. The clinical success of the phase 2 studies relies on the successful enrichment of patients with 
targetable gene fusions. Because of the rarity of NTRK-rearranged tumors and the success of the phase 1 trial, patients are 
being enrolled based on molecular, rather than histological, criteria. 
 
 
 
 
 Sitravatinib (24, MGCD516) is a multi-kinase inhibitor under clinical development by Mirati Therapeutics Inc. 
with activity against RTKs including MET, AXL, MER, and members of the VEGFR, PDGFR, DDR2, TRK and Eph 
families.
190
 A phase 1/1b study is currently recruiting to evaluate dose and preliminary efficacy in patients harboring gene 
rearrangements involving MET, RET, AXL, or NTRK1/2/3 (NCT02219711).
210
 Based on pre-clinical data, sitravatinib is 
likely to be effective for metastatic, soft-tissue sarcomas. Similar to entrectinib, the clinical success of sitravatinib will rest 
on the ability to appropriately enrich patients for targetable, molecular lesions. Although blockade of multiple driver 
signaling pathways can be achieved with sitravatinib,
190
 clinical investigation must identity a therapeutic window to safely 
target NTRK rearrangements without breaching dose-limiting toxicity on other kinase pathways. 
 DS-6051b is under clinical development by Daiichi Sankyo, Inc. for advanced solid tumors harboring ROS1 or 
NTRK1/2/3 rearrangements. A phase 1, two-part clinical trial is underway to determine dose-limiting toxicities and tumor 
response for up to two years (NCT02279433). Results from a phase 1 trial in Japanese subjects have already been 
published with dose-limiting toxicities experienced at the highest dose of 800 mg QD (NCT02675491).
211
 Tolerability in 
American subjects was similar, with dose-limiting toxicities experienced at 800 and 1,200 mg QD.
212
 Partial responses, 
based on tumor regression, were observed at or above the maximum tolerated dose warranting additional safety studies 
and better patient enrichment for a more durable, clinical response. 
 Cabozantinib (23, COMETRIQ®) is a pan-kinase inhibitor developed by Exelixis with FDA approval to treat 
metastatic medullary thyroid cancer (mMTC) and renal cell carcinoma (RCC). Cabozantinib was first approved to treat 
mMTC in 2012 and later, in 2016, it was approved for RCC. Because of its pan-kinase profile demonstrating activity 
against c-Met, RET, ROS1, ALK, VEGFR2, and TRK receptors, cabozantinib is under phase II clinical investigation for 
patients harboring NTRK1 gene fusions in NSCLC (NCT01639508). In the same trial, the drug is being evaluated against 
patients with RET, ROS1, MET, and AXL oncogenes. Cabozantinib has been found to increase the risk of gastrointestinal 
perforations, fistulas, and hemorrhage and carries a black box warning for these side effects. In head-to-head studies, 
entrectinib exhibits stronger inhibition of NTRK fusion genes compared to cabozantinib, which suggests the clinical utility 
of entrectinib might be greater.
161
 Further, cabozantinib inhibits VEGFR2 at an IC50 of 0.000035 µM
213
 and other tyrosine 
kinases >0.001 µM, which positions cabozantinib as a highly potent, selective, and unique VEGFR2 inhibitor.  The 
clinical utility of an inhibitor with strong VEGFR2 selectivity must be further evaluated for usefulness against TRK-
 
 
 
 
driven disease. Because of the pan-kinase profile of cabozantinib, clinical response against TRK cancers can be robust, 
but this also must be weighed against the high propensity for DLTs. Phase II clinical investigation will further evaluate 
the usefulness of cabozantinib in safely treating TRK-driven cancers. 
A major clinical major consideration for TRK inhibitors is the propensity to select for drug resistant TRK 
mutations. For example, a metastatic colorectal cancer patient harboring a NTRK1 gene fusion displayed a marked 
response to entrectinib.
160
 However, after 4 months of treatment, entrectinib lost effectiveness in controlling tumor 
growth. By monitoring circulating tumor DNA (ctDNA), it was identified that the TRKA kinase domain underwent two 
different point mutations at G595R and G667C. These point mutations were also shown to limit the TRKA inhibitory 
activity of larotrectinib and belizatinib.
160
 To overcome TRK resistant mutations, LOXO-195 (9) was developed, which is 
a constrained analogue of larotrectinib. Due to conformational limitations, steric interactions with TRKA G667C and 
TRKC G623R (homologous to TRKA G595R) are limited and kinase inhibitory activity is maintained. These results have 
been translated into clinical trials where patients have responded to LOXO-195 after failing treatment with larotrectinib.
159
 
Clinical trials for LOXO-195 are ongoing and are displaying the potential to extend durable remissions in patients with 
TRK-resistant lesions (NCT03215511). 
Conclusion and Future Perspective for TRK Inhibitors 
The use of kinase-directed precision medicine has been heavily pursued since the discovery and development of 
imatinib.
42
 Kinases have since emerged as one of the most intensely pursued drug targets in oncology research due to 
highly druggable active sites and their critical roles in cellular signaling. However, there has yet to be a clinically 
approved inhibitor for the TRK-receptor tyrosine kinase despite its intimate involvement in tumor pathology and disease. 
The vast majority of kinase inhibitors developed for TRK exhibit limited selectivity against any of the three isoforms 
(TRKA/B/C) and are active in the greater kinome. These types of inhibitors will have limited utility as tools to further 
study TRK biology but have exhibited excellent therapeutic potential in clinical trials, especially when patients treated 
with TRK inhibitors are selected based on their molecular pathology.  To further study TRK biology, it will be beneficial 
to utilize highly selective inhibitors with activity specific for a single, TRK isoform, such as 41 for TRKA.  This will 
permit the inhibition of a single enzyme in the TRK family, which can help identify isoform importance and interplay in a 
variety of preclinical TRK-models.  It is important to note that TRK singling, specifically via their corresponding growth 
 
 
 
 
factors,
214
 has been implicated in mediating and modulating the pain response.  As such beyond cancer, TRK inhibitors 
are being evaluated in clinical trials as agents to reduce neuropathic pain (NCT03346330). 
The most clinically advanced TRK inhibitors include entrectinib, a pan-TRK, ALK and ROS inhibitor, and 
larotrectinib, a specific, pan-TRK inhibitor. Both larotrectinib and entrectinib have achieved orphan designation from 
regulatory authorities.
48
 A recent report of the clinical activity of entrectinib in 55 TRK mutant patients displayed an 80% 
overall response rate with long-lasting responses in 71% of patients (> 12-months).
100
 An aspect that needs to be 
considered in the development of TRK inhibitors is, given their role in the nervous system, the possibility of adverse 
neuropsychiatric effects. One parameter that may influence this property is activity in the greater kinome and, another, the 
ability to cross the blood-brain barrier. Noteworthy, the most advanced TRK inhibitors under clinical development, such 
as larotrectinib and entrectinib, exhibited neurotoxicity. This is likely due to target specificity, although they are able to 
penetrate the blood-brain barrier and exert therapeutic effects against brain metastases.
48 The identification of the clinical 
candidate PF-06273340 (22-3) provides a strategy to deliver peripherally restricted and orally bioavailable compounds, 
which was to design compounds in physicochemical space appropriate for absorption across the gastrointestinal 
epithelium while, simultaneously, engineering the compounds as substrates for blood−brain barrier efflux transporters.186, 
201
  
As observed with all kinase inhibitors, TRK resistance to precision medicine is a major therapeutic limitation for 
durable efficacy. To overcome resistance, LOXO-195 was developed and is exhibiting effectiveness to induce remissions 
in patients that have failed larotrectinib treatment. The exact duration of remission is being investigated in clinical trials, 
and the development of LOXO-195 is a hopeful addition for treating TRK-driven disease. Clinical studies have confirmed 
the importance of selecting patients based on molecular criteria, and this enrichment will become even more important 
when transitioning from 1st to 2nd generation TRK inhibitors. Although all evaluation of TRK precision medicine is in 
the early stages of clinical development, significant breakthroughs have been uncovered for the treatment and 
management of TRK-driven tumors. With the completion of clinical studies incorporating larger patient populations it is 
expected that TRK precision medicine will continue to exhibit efficacy. Larger clinical studies will also illuminate if 
selective (larotrectinib) or pan-kinase inhibitors (entrectinib) are more appropriate for treating TRK malignancies.  With 
the advent of routine molecular profiling of tumors, patients will be treated with TRK precision medicine to induce a 
 
 
 
 
tailored response. This will translate to customized treatment profiles that will better target the unique pathology of a 
patient’s tumor. 
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